The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell ...
After a delayed approval, treosulfan’s manufacturer is hopeful the alkylating agent will become the new gold standard in the United States.
Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million ...
The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell ...
Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...
The FDA has approved GRAFAPEXâ„¢ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...
The Food and Drug Administration (FDA) has approved Grafapex â„¢ (treosulfan) for injection with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...
The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...
Shares were up 30% to 5.18 Canadian dollars Wednesday. Medexus will target a commercial launch in the first half of calendar 2025. The company believes product-level revenue in the U.S. has the ...
GRAFAPEXâ„¢ (treosulfan) for injection is approved by the FDA for sale and use in the United States only and is not intended for export outside the United States. Medexus makes no representation that ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell ...